Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections

1. A compound of Formula (I):

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R 1 is an atom or group removed in vivo to form OH when administered as the parent nucleoside,

ii) W is, independently, N, CH, CF, CCN, CC ≡CH, or CC(O)N(R′) 2 ;

iii) Sugar is ribose or modified ribose of the general formula (II):

wherein:

Y is O or S;

Z is selected from the group consisting of CL 2 , CL 2 CL 2 , CL 2 OCL 2 , CL 2 SCL 2 , CL 2 O, OCL 2 and CL 2 NHCL 2 , wherein L independently is selected from the group consisting of H, F, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl, wherein C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl may each optionally contain one or more heteroatoms;

A is O, S, CH 2 , CHF, CF 2 , C═CH 2 , C═CHF, or C═CF 2 ;

R 4′ , R 5 , R 5′ , R 6 , R 6′ , and R 7′ are independently selected from the group consisting of H, F, Cl, Br, I, OH, SH, NH 2 , NHOH, NHNH 2 , N 3 , C(O)OH, CN, C(O)NH 2 , C(S)NH 2 , C(O)OR, R, OR, SR, SSR, NHR, and NR 2 ;

wherein for formula (I) where sugar is formula (II), when A is O, and R 4′ , R 5 , R 5′ , R 6 , R 7′ are H, R 6′ cannot be N 3 ;

wherein for formula (I) where sugar is formula (II), when A is O or S R 7′ cannot be OH, SH, NH 2 , NHOH, NHNH 2 , OR, SR, SSR, NHR, and NR 2;

R is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, aryl, alkylaryl, or arylalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of hydroxyalkyl, aminoalkyl, and alkoxyalkyl,

R 2 is O-phenyl, where phenyl is substituted with (CH 2 ) 1-6 CO 2 R 9a , and, optionally, one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, (CH 2 ) 1-6 CO 2 R 9a , halogen, C 1-6 haloalkyl, —N(R 9a ) 2 , C 1-6 acylamino, —NHSO 2 C 1-6 alkyl, —SO 2 N(R 9a ) 2 , —SO 2 C 1-6 alkyl, COR 9b , nitro and cyano;

and R 3 is selected from:

(a) OR 8 where R 8 is H, C 1-20 alkyl, C 3-6 cycloalkyl, C 1-6 haloalkyl, aryl, or heteroaryl optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, (CH 2 ) 1-6 CO 2 R 9a , halogen, C 1-6 haloalkyl, —N(R 9a ) 2 , C 1-6 acylamino, —NHSO 2 C 1-6 alkyl, —SO 2 N(R 9a ) 2 , —SO 2 C 1-6 alkyl, COR 9b , nitro and cyano;

R 9a is independently H or C 1-6 alkyl;

R 9b is —OR 9a or —N(R 9a ) 2 ;

where R 10a and R 10b are:

(i) independently selected from the group consisting of H, C 1-10 alkyl, —(CH 2 ) r NR 9a 2 , C 1-6 hydroxyalkyl, —CH 2 SH, —(CH 2 ) 2 S(O) p Me, —(CH 2 ) 3 NHC(═NH)NH 2 , (1H-indol-3-yl) methyl, (1H-imidazol-4-yl)methyl, —(CH 2 ) m COR 9b , aryl and aryl-C 1-3 alkyl, said aryl groups optionally substituted with a group selected from the group consisting of hydroxyl, C 1-10 alkyl, C 1-6 alkoxy, halogen, nitro, and cyano;

(ii) R 10a is H and R 10b and R 12 together are (CH 2 ) 2-4 to form a ring that includes the adjoining N and C atoms;

(iii) R 10a and R 10b together are (CH 2 ) n to form a ring;

(iv) R 10a and R 10b both are C 1-6 alkyl; or

(v) R 10a is H and R 10b is H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 Ph, CH 2 -indol-3-yl, —CH 2 CH 2 SCH 3 , CH 2 CO 2 H, CH 2 C(O)NH 2 , CH 2 CH 2 COOH, CH 2 CH 2 C(O)NH 2 , CH 2 CH 2 CH 2 CH 2 NH 2 —CH 2 CH 2 CH 2 NHC(NH)NH 2 , CH 2 -imidazol-4-yl, CH 2 OH, CH(OH)CH 3 , CH 2 ((4′-OH)-Ph), CH 2 SH, or C 3-6 cycloalkyl;

p is 0 to 2;

r is 1 to 6;

n is 4 or 5;

m is 0 to 3;

R 11 is H, C 1-10 alkyl, or C 1-10 alkyl substituted with a C 1-6 alkyl, alkoxy, di(C 1-6 alkyl)-amino, fluoro, C 3-10 cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C 1-5 alkyl, or C 1-5 alkyl substituted with a lower C 1-6 alkyl, alkoxy, di(C 1-6 alkyl)-amino, fluoro, C 3-10 cycloalkyl, or cycloalkyl;

R 12 is H, C 1-3 alkyl, or R 10a , or R 10b and R 12 together are (CH 2 ) 2-4 so as to form a ring that includes the adjoining N and C atoms;

(c) an O attached lipid, an N or O attached peptide, an O attached cholesterol, or an O attached phytosterol;

(d) R 2 and R 3 may come together to form a ring

 where W 2 is selected from the group consisting of phenyl or monocyclic heteroaryl, optionally substituted with one to three substituents independently selected from the group consisting of C 1-6 alkyl, CF 3 , C 2-6 alkenyl, C 1-6 alkoxy, OR 9c , CO 2 R 9a , COR 9a , halogen, C 1-6 haloalkyl, —N(R 9a ) 2 , C 1-6 acylamino, CO 2 N(R 9a ) 2 , SR 9a , —NHSO 2 C 1-6 alkyl, —SO 2 N(R 9a ) 2 , —SO 2 C 1-6 alkyl, COR 9b , and cyano, and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that:

a) when there are two heteroatoms and one is O, then the other can not be O or S, and

b) when there are two heteroatoms and one is S, then the other can not be O or S;

R 9a is independently H or C 1-6 alkyl;

R 9b is —OR 9a or —N(R 9a ) 2 ;

R 9c is H or C 1-6 acyl;

 where R 13 is selected from the group consisting of H, C 1-10 alkyl, C 1-10 alkyl optionally substituted with a C 1-6 alkyl, alkoxy, di(C 1-6 alkyl)-amino, fluoro, C 3-10 cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C 1-5 alkyl, or C 1-5 alkyl substituted with a C 1-6 alkyl, alkoxy, di(C 1-6 alkyl)-amino, fluoro, C 3-10 cycloalkyl, or C 3-6 cycloalkyl;

f) R 2 and R 3 may come together to form a ring

 where R 14 is: (i) independently selected from the group consisting of H, C 1-10 alkyl, —(CH 2 ) r NR 2 9a , C 1-6 hydroxyalkyl, —CH 2 SH, —(CH 2 ) 2 S(O) p Me, —(CH 2 ) 3 NHC(═NH)NH 2 , (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, —(CH 2 ) m COR 9b , aryl and aryl-C 1-3 alkyl or heteroaryl and heteroaryl-C 1-3 alkyl, said aryl and heteroaryl groups optionally substituted with a group selected from the group consisting of hydroxyl, C 1-10 alkyl, C 1-6 alkoxy, halogen, nitro, and cyano; (ii) R 14 is H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 Ph, CH 2 -indol-3-yl, —CH 2 CH 2 SCH 3 , CH 2 CO 2 H, CH 2 C(O)NH 2 , CH 2 CH 2 COOH, CH 2 CH 2 C(O)NH 2 , CH 2 CH 2 CH 2 CH 2 NH 2 , CH 2 CH 2 CH 2 NHC(NH)NH 2 , CH 2 -imidazol-4-yl, CH 2 OH, CH(OH)CH 3 , CH 2 ((4′-OH)-Ph), CH 2 SH, or lower cycloalkyl;

p is 0 to 2;

r is 1 to 6;

m is 0 to 3

Q 1 is NR 9a , O, or S

Q 2 is C 1-10 alkyl, C 1-6 hydroxyalkyl, aryl and aryl-C 1-3 alkyl, heteroaryl and heteroaryl-C 1-3 alkyl, said aryl and heteroaryl groups optionally substituted with a group selected from the group consisting of hydroxyl, C 1-10 alkyl, C 1-6 alkoxy, fluoro, and chloro;

R 11 is H, C 1-10 alkyl, C 1-10 alkyl optionally substituted with a C 1-6 alkyl, alkoxy, di(C 1-6 alkyl)-amino, fluoro, C 3-10 cycloalkyl, cycloalkyl alkyl, cycloheteroalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; wherein the substituents are C 1-5 alkyl, or C 1-5 alkyl substituted with a C 1-6 alkyl, alkoxy, di(C 1-6 alkyl)-amino, fluoro, C 3-10 cycloalkyl, or cycloalkyl;

R 12 is H or C 1-3 alkyl, or R 14b and R 12 together are (CH 2 ) 2-4 so as to form a ring that includes the adjoining N and C atoms;

iv) alternatively Sugar is a modified ribose of the general formula (III):

wherein:

wherein for formula (I) where sugar is formula (III), when A is O or S R 7′ cannot be OH, SH, NH 2 , NHOH, NHNH 2 , OR, SR, SSR, NHR, and NR 2 ,

R is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, aryl, alkylaryl, or arylalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of hydroxyalkyl, aminoalkyl, and alkoxyalkyl;

v) alternatively Sugar is a dioxolane or a oxathiolane of the general formulas (IV), (V), (VI), and (VII):

wherein:

V is S or Se

vi) alternatively Sugar is a modified ribose of the general formulas (XI):

wherein:

R 19 is H, F, Cl, Br, I, N 3 , C(O)OH, CN, C(O)NH 2 , C(S)NH 2 , C(O)OR, R

R is independently a C 1-6 alkyl (C 1 -C 6 alkyl), C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl aryl, alkylaryl, or arylalkyl, wherein the groups can be substituted with one or more substituents selected from the group consisting of hydroxyalkyl, aminoalkyl, and alkoxyalkyl,

wherein the compounds can be in the form of the β-L- or β-D-configuration, or a mixture thereof, including a racemic mixture thereof.

2. The compound of claim 1 , wherein R 6′ selected from the group consisting of H, F, Cl, Br, I, OH, SH, NH 2 , NHOH, NHNH 2 , C(O)OH, CN, C(O)NH 2 , C(S)NH 2 , C(O)OR, R, OR, SR, SSR, NHR, and NR 2 .

3. The compounds of claim 1 , wherein R 5 is selected from the group consisting of NH 2 , dimethylamine, methyl-allyl-amine, methoxy, chloro, cyclopropylamine, 5-hydroxy-pentylamine, 1,1-dimethyl-ethanolamine, and 2-methoxy-ethylamine.

4. The compounds of claim 1 , wherein the compounds are in the β-L- or β-D configuration, or a racemic mixture thereof.

5. A method for treating a host infected with HIV-1 or HIV-2, or reducing the biological activity of an HIV-1 or HIV-2 infection in a host, comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment thereof.

6. The method of claim 5 , wherein the HIV-1 or HIV-2 infection is caused by a virus comprising a mutation selected from the group consisting of TAM mutations and the M184V mutation.

7. The method of claim 5 , wherein the compound is administered in combination with another anti-HIV agent.

8. The method of claim 7 , wherein the HIV-1 or HIV-2 infection is caused by a virus comprising a mutation selected from the group consisting of TAM mutations and the M184V mutation.

9. A method for treating a host infected with HBV, or for reducing the biological activity of an HBV infection in a host, comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment thereof.

10. The method of claim 7 , wherein the compound is administered in combination with another anti-HBV agent.

11. A method for treating a host infected with Norovirus or Saporovirus, or reducing the biological activity of an Norovirus or Saporovirus infection in a host, comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment thereof.

12. The method of claim 11 , wherein the compound is administered in combination with another anti-Norovirus or anti-Saporovirus agent.

13. A method for treating a host infected with a Flaviviridae virus or reducing the biological activity of an infection with a Flaviviridae virus in a host, comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment thereof.

14. A method for treating a host infected with HSV-1 or HSV-2, or reducing the biological activity of an HSV-1 or HSV-2 infection in a host, comprising administering an effective amount of a compound of claim 1 to a patient in need of treatment thereof.

15. The method of claim 10 , wherein the compound is administered in combination with another anti-HSV-1 AND HSV-2 agent.

16. The compound of claim 1 , wherein R 1 is selected from the group consisting of halogen, OR′, N(R′) 2 , SR′, OCOR′, NHCOR′, N(COR′)COR′, SCOR′, OCOOR′, and NHCOOR′, and wherein each R′ is independently H, a C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, aryl, heteroaryl, alkylaryl, or arylalkyl, wherein the groups can be substituted with one or more hydroxyalkyl, aminoalkyl, or alkyoxyalkyl substituents.

17. The method of claim 13 , wherein the virus is selected from the group consisting of HCV, Yellow fever, Dengue, and West Nile virus.

18. A compound of claim 1 or a pharmaceutically acceptable salt or prodrug thereof, wherein the lipid is a phospholipid.